Phreesia, Inc. Class Action Lawsuit - PHR
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Phreesia class action lawsuit seeks to represent purchasers or acquirers of Phreesia, Inc. (NYSE: PHR) common stock between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”). Captioned Theodoulou v. Phreesia, Inc., No. 26-cv-00556 (D. Del.), the Phreesia class action lawsuit charges Phreesia and certain of Phreesia’s top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Phreesia class action lawsuit, please provide your information in the form on this page. You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Phreesia class action lawsuit must be filed with the court no later than July 13, 2026.
CASE ALLEGATIONS: Phreesia provides an integrated SaaS-based software and payment platform for the healthcare industry.
The Phreesia class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Phreesia’s long-term growth outlook through expansion of its key revenue platforms and remained confident in its revenue growth projections for fiscal year 2027, while also minimizing risks from slowing growth in its Network Solutions segment; and (ii) Phreesia’s portrayal of its pharmaceutical marketing commitments as a durable growth driver of its Network Solutions segment was uncertain thereby putting the 2027 revenue target at risk.
The Phreesia class action lawsuit further alleges that on March 30, 2026, defendants published their fourth quarter and fiscal year 2026 earnings, revealing that Phreesia was significantly reducing its revenue guidance for fiscal year 2027 due to little growth expected in its Network Solutions segment. Specifically, the complaint alleges that Phreesia announced its 2027 revenue guidance in the range of $510 million to $520 million, down substantially from its previous guidance of $545 million to $559 million. On this news, the price of Phreesia’s common stock fell approximately 27%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Phreesia common stock during the Class Period to seek appointment as lead plaintiff in the Phreesia class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Phreesia class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Phreesia class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Phreesia class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.